Using interactions between viral peptides and human proteins as a starting point, researchers from Enyo Pharma Inc., the University of Lyon and other institutions were able to bootstrap themselves to a mitochondria-targeting small molecule that showed activity in a mouse model of nonalcoholic steatohepatitis (NASH) with chronic kidney disease.
Arcus Biosciences Inc. has synthesized tyrosine-protein kinase receptor UFO (AXL) inhibitors reported to be useful for the treatment of viral infection, cancer and fibrosis.
Axonis Therapeutics Inc. has disclosed dual specificity mitogen-activated protein kinase kinase (MAP2K7; MKK7) inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis, spinal cord injury, multiple sclerosis, neurodegeneration, lysosomal storage, Parkinson’s disease, Huntington’s disease and Alzheimer’s disease, among others.
Proteinlogic Ltd. and Stellenbosch University have received a $1.35 million grant from the Bill & Melinda Gates Foundation to develop a blood test to monitor treatment responses to tuberculosis (TB) antimicrobial chemotherapy.
Despite treatment with temozolomide and radiation therapy, patients with glioblastoma usually develop refractory disease, and thus have a poor prognosis (median overall survival of 15 months); here, the DNA damage response (DDR) mechanism shown by cancer cells plays a key role.
Chinese researchers have presented data on a novel six-gene prognostic risk model for breast cancer based on data from the The Cancer Genome Atlas (TCGA) database.
Sanyou Biopharmaceuticals (Shanghai) Co. Ltd. has launched its Sanyou Super Trillion Peptide Molecule Discovery Platform, suitable for the R&D of peptide-based drugs targeting diseases associated with metabolism and tumors, as well as applications in medical imaging, molecular diagnostics and other fields.
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive form of leukemia that accounts for around 25% of ALL cases. In recent years, novel strategies have emerged to reduce the dependence on intensive chemotherapy or hematopoietic stem cell transplantation, but there is still a need for new options with better efficacy in this setting.
The identification of novel immunotherapeutic targets for the treatment of biliary tract cancer (BTC) is still a need. It has been reported that galectin-9 (GAL-9) is expressed in BTC and induces immunosuppressive effects, such as inducing apoptosis in T cells when binding to its receptor TIM-3.
RSS
